



ATTORNEYS AT LAW



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cormwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr
Michael V. Messinger
Judith U. Kim
Patrick E. Garrett

Jeffrey T. Helvey
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowitz
Peter A. Jackman
Jeffrey S. Weaver
Brian J. Del Buono
Mark Fox Evans
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Daniel A. Klein
Jason D. Eisenberg
Michael D. Specht

Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longsworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Young Tang

Christopher J. Walsh
W. Blake Coblenz*
James J. Pohl*
John T. Haran
Mark W. Rygiel
Kevin W. McCabe
Michael R. Malek*
Doyle A. Siever*
Ulrike Winkler*

Scott M. Woodhouse
Peter A. Socarras
Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
•Practice Limited to
Federal Agencies

March 19, 2007

WRITER'S DIRECT NUMBER:
(202) 772-8769

INTERNET ADDRESS:
BSKELTON@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1624

Attn: Mail Stop Amendment

Re: U.S. Patent Application
Application No. 10/561,174; Filed: June 6, 2006
For: **Triazolopyrimidines**
Inventors: GEBAUER *et al.*
Our Ref: 2400.0090000/VLC/BLS

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement under 37 C.F.R. § 1.97(b);
2. Form PTO/SB/08A (2 sheets);
3. Form PTO/SB/08B (2 sheets);
4. Copies of twenty-seven (27) cited references (FP1 - FP14 and NPL1 - NPL 13); and
5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
March 19, 2007
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Bryan L. Skelton
Attorney for Applicants
Registration No. 50,893

BLS/egw
Enclosure(s)

654605v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GEBAUER *et al.*

Appl. No.: 10/561,174

§ 371(c) Date: June 6, 2006

For: **Triazolopyrimidines**

Confirmation No.: 1957

Art Unit: 1624

Examiner: MOORE, Susanna

Atty. Docket: 2400.0090000/VLC/BLS

**Information Disclosure Statement
under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents **FP1** to **FP14** and **NPL1** to **NPL13** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and a patent application publication cited on the attached Form PTO/SB/08A, documents **US1** to **US3**, are not submitted.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following discussion of the relevance of the non-English language documents, **FP2** to **FP3**, **FP5**, **FP8**, and **FP11**, cited on Form PTO/SB/08A:

Document **FP2**, DE 38 20 538 A1, is in the German language. An English language equivalent of document FP2 is cited as document **FP1** and submitted herewith.

Document **FP3**, WO 95/28370 A1, is in the German language. An English language abstract of document FP3 can be found on the face page of the published patent application.

Document **FP5**, WO 97/16971 A1, is in the German language. An English language abstract of document FP5 can be found on the face page of the published patent application.

Document **FP8**, FR 2 784 380 A1, is in the French language. An English language abstract of document FP8 is cited as document **NPL11** and submitted herewith.

Applicants' would also like to bring to the attention of the Examiner that, for the following document, the volume could not be determined to the best of the Applicants' ability: Chesterfield, J., *et al.*, "Pyrimidines. Part VIII. Halogeno and Hydrazino pyrimidines," *J. Chem. Soc.* :3478-3481, Royal Society of Chemistry (1955).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may

not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Bryan L. Skelton
Attorney for Applicants
Registration No. 50,893

Date: MARCH 19, 2007

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

647757v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Do not submit a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/561,174
		§ 371(c) Date	June 6, 2006
		First Named Inventor	GEBAUER, Olaf
		Art Unit	1624
		Examiner Name	MOORE, Susanna
Sheet	1	of	2
		Attorney Docket Number	2400.009000/VLC/BLS

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

off

2

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
	FP1	GB 2 206 114 A	12/29/1988	Sandoz Ltd.	
	FP2	DE 38 20 538 A1	01/05/1989	Sandoz-Patent-GmbH	
	FP3	WO 95/28370 A1	10/26/1995	Bayer Aktiengesellschaft	Abs
	FP4	WO 96/37494 A1	11/28/1996	Zeneca Limited	
	FP5	WO 97/16971 A1	05/15/1997	Bayer Aktiengesellschaft	Abs
	FP6	WO 98/25923 A1	06/18/1998	Zeneca Limited	
	FP7	WO 99/32464 A1	07/01/1999	Novartis AG; Novartis-Erfindungen Verwaltungsgesellschaft mbH	
	FP8	FR 2 784 380 A1	04/14/2000	American Cyanamid Company	Abs
	FP9	WO 01/11965 A1	02/22/2001	Aventis CropScience GmbH	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Equivalent of Form PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

 INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>	<i>Complete if Known</i>
Sheet 2 of 2	Attorney Docket Number 2400.009000/VLC/BLS
	Application Number 10/561,174
	§ 371(c) Date June 6, 2006
	First Named Inventor GEBAUER, Olaf
	Art Unit 1624
	Examiner Name MOORE, Susanna

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2 of 2

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ² Number ³ Kind Code ⁴ (if known)			
	FP10	WO 01/26468 A2	04/19/2001	Syngenta Participations AG	
	FP11	DE 101 21 162 A1	10/31/2002	Bayer AG	
	FP12	WO 03/039259 A1	05/13/2003	Syngenta Limited; Syngenta Participations AG	
	FP13	WO 03/045877 A1	06/05/2003	Agroqualita' S.R.L.	
	FP14	WO 03/096811 A1	11/27/2003	Monsanto Technology, LLC	


645543v1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP. 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁵ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Equivalent of Form PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

TRADEMARK OFFICE
for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/561,174
§ 371(c) Date	June 6, 2006
First Named Inventor	GEBAUER, Olaf
Art Unit	1624
Examiner Name	MOORE, Susanna
Attorney Docket Number	2400.0090000/VLC/BLS

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	NPL1	Chesterfield, J., et al., "Pyrimidines. Part VIII. Halogeno- and Hydrazino-pyrimidines," <i>J. Chem. Soc.</i> :3478-3481, Royal Society of Chemistry (1955)	
	NPL2	Database Biosis Biosciences Information Service, Abstract No. PREV199395107787, Valdes, M., et al., "Response of Leucaena esculenta to endomycorrhizae and Rhizobium inoculation," <i>World J. Microbiol. Biotechnol.</i> 9:97-99, Kluwer Academic Publishers (1993)	
	NPL3	Derwent Accession No. 1987-046595, English language abstract for JP 62-4207	
	NPL4	Derwent Accession No. 1996-482062, English language abstract for JP 08-245314	
	NPL5	Derwent Accession No. 1999-018249, English language abstract for JP 10-287502	
	NPL6	Derwent Accession No. 1999-544922, English language abstract for JP 11-236301	
	NPL7	Derwent Accession No. 2001-605011, English language abstract for JP 2001-151611	
	NPL8	Derwent Accession No. 2003-461737, English language abstract for JP 2003-055118	
	NPL9	Derwent Accession No. 2003-783317, English language abstract for JP 2003-212708	
	NPL10	STN Database, Accession No. 135:1674, English language abstract for JP 2001-151611	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/561,174
				§ 371(c) Date	June 6, 2006
				First Named Inventor	GEBAUER, Olaf
				Art Unit	1624
				Examiner Name	MOORE, Susanna
Sheet	2	of	2	Attorney Docket Number	2400.0090000/VLC/BLS

NON-PATENT LITERATURE DOCUMENTS

645540v1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This application for registration is subject to 37 CFR 1.62. The information is recorded to obtain or retain a benefit by the public which is to file

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.